Sep 09, 2020 8:30am EDT Veru to Participate and Present at Four Upcoming Healthcare Investor Conferences
Aug 18, 2020 8:30am EDT Veru Extends Agreement with Roman for Veru’s Premature Ejaculation Treatment Product
Aug 04, 2020 8:30am EDT VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19
Jul 30, 2020 8:30am EDT Veru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13th
Jul 27, 2020 8:30am EDT Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation
Jul 23, 2020 8:30am EDT Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer
Jun 19, 2020 8:30am EDT Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19
